Lakewood-Amedex Biotherapeutics, Inc. (LABT) News
Track canonical SquawkNews coverage tagged to LABT, Lakewood-Amedex Biotherapeutics, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 6 indexed stories across 5 publication days and is ordered by the same first-publication timeline used by LiveCast.
H
Crude Oil Gains 2%; GE Vernova Shares Fall After Q2 Earnings
U.S. stocks traded mostly higher midway through trading, with the Dow Jones index gaining more than 200 points on Wednesday. The Dow traded up 0.40% to 52,432.64 while the NASDAQ declined 0.01% to 25,834.80. The S&P 500
MACRO | Jul 22, 2026, 04:09 PM UTC
H
Lakewood-Amedex supports reintroduction of PASTEUR act
Lakewood-Amedex Biotherapeutics announced its support for the reintroduction of the bipartisan Pioneering Antimicrobial Subscriptions to End Upsurging Resistance, PASTEUR, Act, legislation designed to "encourage" the dev
EQUITY | Jul 07, 2026, 12:10 PM UTC
M
12 Health Care Stocks Move
Twelve health care stocks are moving in Thursday's after-market session, with Shuttle Pharmaceuticals and INVO Fertility among the gainers and Creative Medical Tech and Catheter Precision among the losers
EQUITY | Jun 25, 2026, 09:05 PM UTC
L
LABT Appoints Study Chair
Lakewood-Amedex Biotherapeutics appoints Dr. David G. Armstrong as study chair for Phase 2a trial of Nu-3 in infected diabetic foot ulcers
EQUITY | Jun 25, 2026, 12:03 PM UTC
M
LABT Secures Patent
Lakewood-Amedex Biotherapeutics secures composition of matter patent for new Bisphosphocin compounds
EQUITY | Jun 22, 2026, 12:03 PM UTC